Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma.
about
Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom.Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancerDistribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss.Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.
P2860
Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma.
@en
type
label
Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma.
@en
prefLabel
Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma.
@en
P2093
P2860
P356
P1433
P1476
Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma.
@en
P2093
P2860
P304
P356
10.3747/CO.19.1004
P577
2012-12-01T00:00:00Z